Chat
 
 
 
Codon Devices Signs Distribution Agreement with Open Biosystems
Expands Access to Industry-Leading Gene Synthesis Offering

CAMBRIDGE, MA and HUNTSVILLE, AL – June 25, 2007 –Codon Devices Inc. and Open Biosystems Inc. announced today that they have entered into an agreement in which Open Biosystems will distribute Codon Devices’ gene synthesis offering in North America. This relationship marries Codon Devices’ high-quality, low-cost synthetic gene development and production ability with Open Biosystems’ dominant full-length cDNA and ORF clone offering, bioinformatics capabilities, and academic focus. It gives Codon Devices greater capability to reach the academic market, which has smaller transactions and more diverse requirements than the commercial market. Conversely, Open Biosystems can now provide researchers with any gene sequence that they need: from off-the-shelf clones to genes synthesized to the customer’s specifications.

Codon Devices is driving wide-spread adoption of high-quality, low-cost synthetic genes. To date, the Company has maintained a minimum order threshold and thus access to its proprietary industrial-scale BioFAB™ production platform has been restricted to researchers with large-scale requirements. Under the terms of the agreement, Open Biosystems, a leading provider of gene analysis tools, will sell and distribute Codon Devices’ gene synthesis offering to researchers with needs that fall below Codon Devices’ minimum order threshold.

“Through its aggressive investments in the BioFAB™ platform, Codon Devices has moved quickly to industrialize synthetic biology and become a world leader in gene synthesis,” said Brian Pollock, Chief Executive Officer, Open Biosystems. “We are delighted to provide our customers with a new product offering that is clearly revolutionizing how life science research is conducted.”

”We are excited to work with Open Biosystems to provide our gene synthesis offering to a wider range of customers,” said John P. Danner, President and Chief Executive Officer, Codon Devices. “This partnership will enable more scientists to access our BioFAB™ platform and harness the power of Constructive Biology™ to rapidly enable new fields of academic research, overcome key obstacles in renewable energy, and streamline the development of new therapeutics.”

About Open Biosystems
Open Biosystems, Inc. is a leader in Gene Analysis developing, manufacturing and marketing genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with high-quality genes for over-expression analysis, RNAi for gene knockdown and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, please visit www.openbiosystems.com.

About Codon Devices
Codon Devices, based in Cambridge, MA, is a privately-held biotechnology company focused on enabling commercial applications of synthetic biology. Codon Devices' proprietary synthesis and design technologies improve the productivity of its industrial, pharmaceutical and academic customers in a paradigm shift to what the Company calls Constructive Biology™. The Company's focus is on developing and delivering high-value products and design services in a variety of application areas, including engineered gene libraries, engineered cells that produce novel pharmaceuticals, improved vaccines, agricultural products, and bio-refineries for the production of industrial chemicals and energy. Codon Devices' BioFAB™ platform uses sophisticated informatics, robotics and sequencing technologies to accurately synthesize genetic codes orders of magnitude more rapidly and cost-effectively than other currently available technology. www.codondevices.com

Contacts
Paul Todd, PhD
Open Biosystems Inc.
256 319-1493
www.openbiosystems.com.
1-888-412-2225 | My Account | Privacy Policy | Terms & Conditions
© 2005-2007 Open Biosystems All Rights Reserved